Vericiguat Cuts Admissions in HFrEF

]]>(MedPage Today) -- Novel oral agent vericiguat modestly reduced mortality and hospitalization among recently decompensated heart failure with reduced ejection fraction (HFrEF) patients in the pivotal VICTORIA trial.Once-daily doses of the soluble...